Author:
Marier Jean-Francois,Mangum Barry,Reid Betsy,Barrett Jeffrey S.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference20 articles.
1. Happu K, Hirschfeld S, Zajicek A. Comparison of the US and EU pediatric initiatives. In: Proceedings of WHO Expert Consultation on Essential Medicines for Children; July 9–13, 2007; Geneva, Switzerland.
2. Zisowsky J, Krause A, Dingemanse J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics. 2010; 2(4):364–388.
3. US Department of Health and Human Services. Pediatric product development. FDA Safety and Innovation Act. Title V for pediatric drugs and devices. Food and Drug Administration Web site.https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049867.htm. Accessed July 1, 2013.
4. Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. 2007;297(5):480–488.
5. Benjamin DK Jr., Smith PB, Jadhav P, Gobburu JV, Murphy MD, Hasselblad V, et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension. 2008;51(4):834–840.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献